We report a patient with an elevated level of serum beta human chorio-gonadotrophin (13-hCG) due to cholangiocarcinoma. This case demonstrates the need for consideration of diagnoses other than germ-cell tumours when a patient presents with a raised B-hCG level. CASE REPORT A 45-year-old man presented initially to a surgical unit with a history of epigastric pain radiating to the right hypochondrium for four months, nausea, vomiting, obstructive jaundice and weight loss of 15kg over two months. After initial investigations, he was transferred to the regional oncology centre. He was deeply icteric on examination, with marked ascites and a four-fingerbreadth hepar palpable in the abdomen. He had sinus tachycardia (rate lOObpm) and was tachypnoeic (respiratory rate 20 breaths per minute). Decreased air entry was noted bibasally, more marked on the right; oxygen saturation was normal. Bilateral pitting oedema to the knees and presacral oedema were also evident. Testes were normal on examination.
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Ultrasound and CT scan showed a moderate rightsided pleural effusion, a small left pleural effusion, small soft tissue masses involving the right anterior pleura and right lung parenchyma and bilateral basal pulmonary collapse/consolidation. Extensive lesions replaced the entire left lobe of liver; smaller deposits in the right lobe, ascites and a peritoneal nodule were noted. Liver function tests were deranged (bilirubin 102 umol/l (normal = 3-18 umol/l), alkaline phosphatase (ALP) 769 U/i (normal = 30-120 U/1). gammaglutaryl transferase (GGT) 235 U/I (normal = 12-58U/1), aspartate transaminase (AST) 139U/I (normal = 10-40 U/1, alanine transaminase (ALT) 54 U/I (normal = 10-56U/1), albumin 2 1 g/l (normal = 35-50 U/1), prothrombin 17.3 seconds (normal = 12-17 seconds), coagulation otherwise normal. Haemoglobin was 10.9 g/dl -normochromic, normocytic, white cell count elevated at 16.7x 109 (neutrophil leucocytosis). Serum tumour markers showed serum beta human chorio-gonadotrophin (B-hCG) 1274 IU/1, alpha-fetoprotein (AFP) 2.4 kU/l, prostate specific antigen (PSA) 0.1 ng/ml, carcinoembryonic antigen (CEA) <0.5 ng/rnl, and CA 19-9 34992 IU/ml. A liver biopsy (performed under ultrasound guidance) revealed poorly differentiated adenocarcinoma. Immunohistochemistry of the tumour cells was negative for CEA, AFP, B-hCG, and cytokeratin 20, positive for cytokeratin 7 and positive for mucin. A repeat CT scan of chest, abdomen and pelvis suggested a lesion in the pancreatic head with a dilated main pancreatic duct. Given the possibility that the patient had a germ cell tumour, and considering his poor performance status he received a single cycle of carboplatin AUC 6 using a dose based on creatinine clearance (calculated by the Cockroft formula using ideal body weight'). Serum CA19-9 and B-hCG levels were repeated on several occasions -the peak values for these were 96,000 IU/ml and 6739 IU/i respectively two days before his death which occurred 25 days after chemotherapy. Postmortem examination revealed that the bulk of the tumour was in the left lobe of the liver, obliterating the biliary tract and directly infiltrating the pancreas. There were metastases to the porta hepatis, adrenal glands, kidneys, The Ulster Medical Journal abdominal wall, multiple ribs and vertebrae and multiple pulmonary infarcts. Histology was in keeping with an intrahepatic bile duct carcinoma, though pancreatic carcinoma could not be excluded. Human chorionic gonadotrophin is produced by syncitiotrophoblasts, and is a glycoprotein which consists of an a and a B subunit. A serum level of B-hCG> 1000 pg/ml (equivalent to 9.3 IU/1) is believed to be highly diagnostic of gonadal (especially nonseminomatous germ cell) tumours.2'3 Lower levels of elevation of the free B-hCG subunit (>100 pg/ml) have previously been demonstrated in patients with gonadal and non-gonadal tumours; in some patients (1-2%) with nonseminomatous germ cell tumours the free B-hCG subunit may he the only identifiable form in the serum. 4 The nongonadal tumours in the series by Marcillac et al included bladder, biliary, pancreatic, and cervical neoplasms. Microparticle enzyme immunoassay was used to measure B-hCG (i.e. free B-hCG and intact hCG) in our case (Axsym system®, Abbott laboratories, Illinois, USA). The degree of elevation of CA 19-9 is consistent with the post mortem findings. The high total B-hCG level is extremely unusual, but may relate to the poorly differentiated nature of this tumour. Serum levels of B-hCG greater than or equal to 4 IU/l have been demonstrated to correlate with poor prognosis in patients with gastric carcinoma, and may represent an independent factor reflecting not just the tumour burden but aggressive biology.5 Raised levels of free B-hCG have also been found to be a poor prognostic factor in advanced colorectal cancer.6 In a small series from Japan, patients with cancer of unknown primary origin and female patients with peritoneal adenocarcinomatosis with elevated 13-hCG (more than 10 IU/1) who received platinum based chemotherapy showed higher response rates than patients with lower values (83.3% and 80% respectively versus 15.3%).7 Elevated preoperative levels of free B-hCG may also correlate with prognosis and survival in patients with epithelial ovarian cancers.8 The method of analysis of B-hCG is important for comparisons between different reports as assays report either free B-hCG or total B-hCG.
Tissue expression of 13-hCG does not always correlate with serum expression of Reasons for this may include a lower detection threshold of the serum assay, and the degree of shedding of antigen which is related to lymphovascular invasion, basal membrane degradation and the extracellular matrix. Elevation of B-hCG measured in the serum can also occur due to heterophilic antibodies,9 and an alternative serum assay would have been useful to exclude this phenomenon. In summary, B-hCG remains a valuable marker in patients with germ cell tumours and trophoblastic disease. We must however, consider other diagnoses in the setting of an elevated serum BhCG (even very high levels as seen in our patient) and a tumour of unknown origin. The atypical clinical presentation as a germ cell tumour should prompt further investigations for alternative primary tumours, although this is unlikely to have affected the management of this patient due to his poor general condition. 
